Sana Biotechnology stock analysis
Want to see SANA full AI Analyst Report?
Sana Biotechnology (SANA) Stock Price & Analysis
SANA Stock Chart & Stats
- Day’s Range
- $1.57 - $1.75
- 52-Week Range
- $1.57 - $5.49
- Previous Close
- $1.74
- Volume
- N/A
- Average Volume (3M)
- 2.92M
- Market Cap
- $521.36M
- Enterprise Value
- $828.47M
- Total Cash (Recent Filing)
- $121.73M
- Total Debt (Recent Filing)
- $53.84M
- Price to Earnings (P/E)
- ―
- Beta
- 1.87
- Next Earnings
- Mar 23, 2027 (Est.)
- EPS Estimate
- -0.17
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improving Losses And Cash Burn
The narrowing loss profile and reduced cash burn indicate improving cost discipline as Sana advances its pipeline. Although the company remains unprofitable, sustained improvement could extend financial runway and reduce the intensity of future capital needs over the next several quarters.
Reduced Leverage
Lower debt and improved leverage provide Sana with a more manageable capital structure for a development-stage biotech. Reduced obligations can limit financing pressure and preserve greater flexibility to direct resources toward clinical development, regulatory preparation, and platform advancement.
Clinical And Pipeline Progress
Clinical validation for UP421 and progress toward an SC451 IND demonstrate advancement beyond purely preclinical research. Durable cell performance and defined regulatory milestones may strengthen the platform’s credibility and create multiple future opportunities for therapeutic development.
Bears Say
No Commercial Revenue
Sana has not yet demonstrated commercial demand or product monetization, so its ability to create shareholder value depends on future clinical success and eventual approvals. Until revenue begins, operating performance remains exposed to development delays and continued reliance on capital resources.
Persistent Cash Burn
Material negative operating and free cash flow means Sana consumes substantial capital while progressing its programs. Continued burn can require external financing or a major revenue step-up, creating funding risk and potentially limiting the pace or breadth of pipeline investment.
Equity Capital Erosion
The large decline in equity reflects prolonged losses consuming the company’s capital base, while deeply negative returns show that current operations are not yet generating economic value. This weakens financial resilience and increases dependence on successful commercialization or additional funding.
Sana Biotechnology News
Sana Biotechnology Faces Investor Lawsuit as Court Weighs Motion to Dismiss Securities Claims Over ARDENT Trial Disclosures
Sana Biotechnology, Inc. ($SANA), a Seattle-based cell therapy company, is at the center of a securities lawsuit in which shareholders allege the company and two executives misled investors about an
Sana Biotechnologies: Mayo Collaboration and HIP Platform Progress Reinforce Buy Rating and Unchanged $7 Price Target
Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Sana Biotechnology, retaining the price target of $7.00. Emily Bodnar has given his Buy rating due to a combination
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
What is Sana Biotechnology’s market cap?
When is Sana Biotechnology’s upcoming earnings report date?
How were Sana Biotechnology’s earnings last quarter?
Is Sana Biotechnology overvalued?
Does Sana Biotechnology pay dividends?
What is Sana Biotechnology’s EPS estimate?
How many shares outstanding does Sana Biotechnology have?
What happened to Sana Biotechnology’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sana Biotechnology?
What is the TipRanks Smart Score and how is it calculated?
Sana Biotechnology Stock Smart Score
Company Description
Sana Biotechnology
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven D. Harr
- Employees
- 142
- Website
- www.sana.com
- Address
- 188 East Blaine Street, Seattle, WA, 98102, US
Sana Biotechnology (SANA) Earnings & Revenues
SANA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |












